𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatitis C genotype 4 therapy: increasing options and improving outcomes

✍ Scribed by Sanaa M. Kamal

Book ID
111238059
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
951 KB
Volume
29
Category
Article
ISSN
0106-9543

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pegylated interferon and ribavirin thera
Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection
✍ F. Legrand-Abravanel; F. Nicot; A. Boulestin; K. Sandres-SaunΓ©; J.P. Vinel; L. A πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 91 KB

## Abstract Hepatitis C Virus (HCV) is classified into six genotypes. Genotype 4 is now spreading in Europe, especially among drug users, who are often infected with both HCV and the human immunodeficiency virus (HIV). Previous studies have shown that HCV‐4 responds poorly to interferon. Pegylated

Mycophenolate mofetil combination therap
Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C
✍ Russell H. Wiesner; Jolene S. Shorr; Bettina J. Steffen; Alice H. Chu; Robert D. πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 121 KB

To evaluate the impact of mycophenolate mofetil (MMF) on long-term outcomes of tacrolimus and corticosteroids, we analyzed data reported to the Scientific Registry of Transplant Recipients for 11,670 adult patients (3463 with hepatitis C [HCV]) who underwent primary, single-organ, liver transplantat

Outcome in partial early virologic respo
Outcome in partial early virologic responders to combination therapy with peginterferon and ribavirin in patients infected with hepatitis C virus genotype 1b
✍ Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Makoto Tanikawa; Yasuhiro Hisan πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 183 KB

## Abstract The course and outcome in patients infected with hepatitis C virus (HCV) genotype 1b with partial early virologic response during combination therapy with peginterferon and ribavirin, in whom serum HCV RNA is detectable but has decreased by more than 2 log~10~ 12 weeks after the start o